72 related articles for article (PubMed ID: 27821443)
41. The interplay between drug resistance and fitness in malaria parasites.
Rosenthal PJ
Mol Microbiol; 2013 Sep; 89(6):1025-38. PubMed ID: 23899091
[TBL] [Abstract][Full Text] [Related]
42. Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications.
Guler JL; Freeman DL; Ahyong V; Patrapuvich R; White J; Gujjar R; Phillips MA; DeRisi J; Rathod PK
PLoS Pathog; 2013; 9(5):e1003375. PubMed ID: 23717205
[TBL] [Abstract][Full Text] [Related]
43. PRICE: software for the targeted assembly of components of (Meta) genomic sequence data.
Ruby JG; Bellare P; Derisi JL
G3 (Bethesda); 2013 May; 3(5):865-80. PubMed ID: 23550143
[TBL] [Abstract][Full Text] [Related]
44. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
45. The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
Skinner-Adams TS; Butterworth AS; Porter KA; D'Amico R; Sawe F; Shaffer D; Siika A; Hosseinipour MC; Stringer E; Currier JS; Chipato T; Salata R; Lockman S; Eron JJ; Meshnick SR; McCarthy JS
PLoS One; 2012; 7(4):e34399. PubMed ID: 22509297
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Porter KA; Cole SR; Eron JJ; Zheng Y; Hughes MD; Lockman S; Poole C; Skinner-Adams TS; Hosseinipour M; Shaffer D; D'Amico R; Sawe FK; Siika A; Stringer E; Currier JS; Chipato T; Salata R; McCarthy JS; Meshnick SR
Antimicrob Agents Chemother; 2012 Feb; 56(2):995-1000. PubMed ID: 22123685
[TBL] [Abstract][Full Text] [Related]
47. Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte.
Russo I; Babbitt S; Muralidharan V; Butler T; Oksman A; Goldberg DE
Nature; 2010 Feb; 463(7281):632-6. PubMed ID: 20130644
[TBL] [Abstract][Full Text] [Related]
48. An aspartyl protease directs malaria effector proteins to the host cell.
Boddey JA; Hodder AN; Günther S; Gilson PR; Patsiouras H; Kapp EA; Pearce JA; de Koning-Ward TF; Simpson RJ; Crabb BS; Cowman AF
Nature; 2010 Feb; 463(7281):627-31. PubMed ID: 20130643
[TBL] [Abstract][Full Text] [Related]
49. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead B; Trapnell C; Pop M; Salzberg SL
Genome Biol; 2009; 10(3):R25. PubMed ID: 19261174
[TBL] [Abstract][Full Text] [Related]
50. Coordination of COPII vesicle trafficking by Sec23.
Fromme JC; Orci L; Schekman R
Trends Cell Biol; 2008 Jul; 18(7):330-6. PubMed ID: 18534853
[TBL] [Abstract][Full Text] [Related]
51. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
Andrews KT; Fairlie DP; Madala PK; Ray J; Wyatt DM; Hilton PM; Melville LA; Beattie L; Gardiner DL; Reid RC; Stoermer MJ; Skinner-Adams T; Berry C; McCarthy JS
Antimicrob Agents Chemother; 2006 Feb; 50(2):639-48. PubMed ID: 16436721
[TBL] [Abstract][Full Text] [Related]
52. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
Parikh S; Gut J; Istvan E; Goldberg DE; Havlir DV; Rosenthal PJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2983-5. PubMed ID: 15980379
[TBL] [Abstract][Full Text] [Related]
53. Antiretrovirals as antimalarial agents.
Skinner-Adams TS; McCarthy JS; Gardiner DL; Hilton PM; Andrews KT
J Infect Dis; 2004 Dec; 190(11):1998-2000. PubMed ID: 15529265
[TBL] [Abstract][Full Text] [Related]
54. The role of Plasmodium falciparum food vacuole plasmepsins.
Liu J; Gluzman IY; Drew ME; Goldberg DE
J Biol Chem; 2005 Jan; 280(2):1432-7. PubMed ID: 15513918
[TBL] [Abstract][Full Text] [Related]
55. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
Coombs GH; Goldberg DE; Klemba M; Berry C; Kay J; Mottram JC
Trends Parasitol; 2001 Nov; 17(11):532-7. PubMed ID: 11872398
[TBL] [Abstract][Full Text] [Related]
56. A structural model for the retroviral proteases.
Pearl LH; Taylor WR
Nature; 1987 Sep 24-30; 329(6137):351-4. PubMed ID: 3306411
[TBL] [Abstract][Full Text] [Related]
57. Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.
Sonoiki E; Nsanzabana C; Legac J; Sindhe KM; DeRisi J; Rosenthal PJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821443
[TBL] [Abstract][Full Text] [Related]
58. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets.
Moon RP; Bur D; Loetscher H; D'Arcy A; Tyas L; Oefner C; Grueninger-Leitch F; Mona D; Rupp K; Dorn A; Matile H; Certa U; Berry C; Kay J; Ridley RG
Adv Exp Med Biol; 1998; 436():397-406. PubMed ID: 9561248
[No Abstract] [Full Text] [Related]
59. Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions.
Miller Iii WA; Teye J; Achieng AO; Mogire RM; Akala H; Ong'echa JM; Rathi B; Durvasula R; Kempaiah P; Kwofie SK
Curr Top Med Chem; 2019; 18(23):2022-2028. PubMed ID: 30499404
[TBL] [Abstract][Full Text] [Related]
60. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
